CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding

Abstract excerpt

OBJECTIVE: The aim of this study was to assess whether the CYP2C9*2 and/or *3 variants might modify the risk for NSAID-related upper gastrointestinal bleeding (UGIB) in NSAID users. PATIENTS AND METHODS: We conducted a multicenter, case-control study in which cases were patients aged more than 18 years with a diagnosis of UGIB, and controls were matched (1 : 3) by sex, age, date of admission, and hospital....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antiplatelet Therapy and Cardiovascular Diseases
• Share to Inflammatory mediators and NSAID effects
• Share to Pharmacogenetics and Drug Metabolism